Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2000
11/02/2000EP1047437A1 Sea cucumber carotenoid lipid fraction products and methods of use
11/02/2000EP1047436A2 Methods of treating tardive dyskinesia and other movement disorders
11/02/2000EP1047428A1 Pharmaceutically active morpholinol
11/02/2000EP1047427A1 Combination of a gaba-a alpha 2/3 agonist and a selective serotonin reuptake inhibitor
11/02/2000EP1047416A2 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
11/02/2000EP1047415A1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
11/02/2000EP1047412A1 New use of local anaesthetics against vascular headaches
11/02/2000EP1047409A1 Tts containing an antioxidant
11/02/2000EP0914331B1 Neuroactive peptides
11/02/2000EP0853619B1 Disubstituted piperidine derivatives
11/02/2000EP0848592B1 Antistress agents for aquatic animals
11/02/2000EP0808312B1 Indole derivatives as 5-ht receptor antagonist
11/02/2000EP0790059A4 Means for treating auto-immune diseases and method of treatment
11/02/2000DE19917990A1 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk Medicines containing inhibitors of cell volume-regulated human kinase h-sgk
11/02/2000CA2371274A1 Selective npy (y5) antagonists
11/02/2000CA2371241A1 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
11/02/2000CA2371064A1 Methods of delivery of cetyl myristoleate
11/02/2000CA2371017A1 Cell therapy for chronic stroke
11/02/2000CA2370241A1 Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
11/02/2000CA2370195A1 Human membrane-associated proteins
11/02/2000CA2369999A1 Enzymatically activated polymeric drug conjugates
11/02/2000CA2369942A1 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
11/02/2000CA2368213A1 Specifically targeted catalytic antagonists and uses thereof
11/02/2000CA2367965A1 Human gil-19/ae289 proteins and polynucleotides encoding same
11/02/2000CA2367695A1 Heteroaryl diazacycloalkanes, their preparation and use
11/02/2000CA2367682A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands
11/02/2000CA2367681A1 Azaindole derivatives for the treatment of depression
11/01/2000CN1272139A Nucleic acids coding for proteins capable of interacting with presenilins
11/01/2000CN1272108A Indole derivatives as 5-HT1B and 5-HT1D agonists
11/01/2000CN1271734A Substituted 19-norsteroid, its preparation and intermediate and its medical use and composition
11/01/2000CN1271731A New thiazole benzimidazole derivative
11/01/2000CN1058013C Process for preparation of novel mercaptoacetylamide derivatives
11/01/2000CN1058009C 8-oxy-5,8-dihydro-6H-dibenzo [a,g] quinolizine -13-propionic acid derivant, its preparation method and medicinal use thereof
11/01/2000CN1058008C Phenyl heterocycles as cyclooxygenase-2 inhibitors
11/01/2000CN1057929C Xueguiling analgesic
10/2000
10/31/2000US6140532 O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
10/31/2000US6140372 Acyl derivatives of melatonin and of melatoninergic analogues and their use as medicinal products
10/31/2000US6140363 Administering rosmarinic acid, its derivative or prunella vulgaris extract for suppressing immune response for treatment, prevention, or diagnosis of rejection of transplanted organ or tissue, chronic rejection
10/31/2000US6140357 Small molecule inhibitors of rotamase enzyme activity
10/31/2000US6140354 N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
10/31/2000US6140352 Carbazolyl-substituted ethanolamines as selective β-3 agonists
10/31/2000US6140345 For treating psychoses and pain
10/31/2000US6140337 Methods for the treatment of mental disorders
10/31/2000US6140336 Spiro[2H-1-benzopyran-2,4'-piperidine]-4(3H)-one derivatives, acid addition salts thereof and pharmaceutical compositions containing them
10/31/2000US6140331 For treating anxiety disorders, depression, psychosis, impulse control disorders, alcohol abuse, ischaemic diseases, cardiovascular disorders, side effects induced by conventional antipsychotic agents and senile dementia
10/31/2000US6140327 Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
10/31/2000US6140321 Polymorphs of donepezil hydrochloride and process for production
10/31/2000US6140309 Inhibiting the vasoactive effects of beta-amyloid peptides by exposing vessel to a modifier of superoxide formation prior to exposure of the vessel to a amyloid peptide
10/31/2000US6140116 Adjusted swine neuronal cells for the treatment of humans with stroke, brain trauma, amyotrophic lateral sclerosis, multiple sclerosis, huntington's and alzheimer's disease
10/31/2000US6140112 Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases
10/31/2000US6139877 Spheroids containing tiagabine, preparation process and pharmaceutical compositions
10/31/2000CA2151724C Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac
10/31/2000CA1341131C Human nerve growth factor
10/27/2000CA2307108A1 Process for production of mammalian cell lines, produced cell lines and their uses
10/27/2000CA2307022A1 Agent for enhancing cerebral acetylcholine release
10/27/2000CA2306574A1 Methods and compositions for treating age-related behavioral disorders in companion animals
10/26/2000WO2000063702A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes
10/26/2000WO2000063441A2 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
10/26/2000WO2000063415A1 Dna encoding the human vanilloid receptor vr1
10/26/2000WO2000063379A2 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
10/26/2000WO2000063374A1 Synthetic transmembrane components
10/26/2000WO2000063372A1 Synthetic signalling molecules
10/26/2000WO2000063370A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
10/26/2000WO2000063367A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof
10/26/2000WO2000063246A2 Compounds and methods for modulating beta-catenin mediated gene expression
10/26/2000WO2000063241A2 Methods and compositions for modulating an immune response
10/26/2000WO2000063230A2 49 human secreted proteins
10/26/2000WO2000063228A1 Ent-steroids as selectively active estrogens
10/26/2000WO2000063215A2 Indazole derivatives, preparation and therapeutic application thereof
10/26/2000WO2000063210A1 Morphinoid compounds
10/26/2000WO2000063208A1 Substituted imidazoles, their preparation and use
10/26/2000WO2000063204A2 Substituted azoles
10/26/2000WO2000063203A1 Piperidine-indole compounds having 5-ht6 affinity
10/26/2000WO2000063190A1 New compounds, their preparation and use
10/26/2000WO2000063181A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
10/26/2000WO2000063179A1 Neurotrophin potentiators
10/26/2000WO2000063169A2 N-dimethyl amino ethanol carboxylate pyrrolidone hydrate in its crystallised form
10/26/2000WO2000063166A1 Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
10/26/2000WO2000063153A1 New compounds, their preparation and use
10/26/2000WO2000062801A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
10/26/2000WO2000062800A2 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
10/26/2000WO2000062798A2 Angiogenic growth factors for treatment of peripheral neuropathy
10/26/2000WO2000062797A1 Remedies for autonomic neuropathy
10/26/2000WO2000062791A1 D-form polypeptide which induces immune tolerance and methods of use
10/26/2000WO2000062786A2 Compositions containing rubidium and in particular rubidium chloride as an antimanic agent and stabilizer for mood swings
10/26/2000WO2000062782A1 Novel synthesis and crystallization of piperazine ring-containing compounds
10/26/2000WO2000062781A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
10/26/2000WO2000062780A1 Use of glucosylceramide synthesis inhibitors in therapy
10/26/2000WO2000062779A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
10/26/2000WO2000062778A1 Cyclic protein tyrosine kinase inhibitors
10/26/2000WO2000062773A1 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
10/26/2000WO2000062770A1 Compounds useful as phosphotyrosine mimics
10/26/2000WO2000062766A2 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/26/2000WO2000062765A2 ESTROGEN RECEPTOR-β LIGANDS
10/26/2000WO2000062764A1 Gum pad for delivery of medication to mucosal tissues
10/26/2000WO2000062757A1 Composition containing opioid antagonists and spray dispenser
10/26/2000WO2000039120A3 Compounds and methods for modulation of estrogen receptors
10/26/2000WO2000037064A3 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
10/26/2000WO2000035919A3 Quinoline derivatives
10/26/2000WO2000032751A3 Mammalian non-neuronal cells that are modified to store and release a neurotransmitter